Cipla USA recalls Nilotinib anti-cancer capsules over manufacturing issue: USFDA

Cipla USA is recalling over 400 cartons of its generic anti-cancer drug Nilotinib Capsules (150 mg and 200 mg) due to a manufacturing issue, the US Food and Drug Administration has said. The recall affects specific batches distributed in the United States.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zEldipu
via IFTTT

Read More

HLL Lifecare to expand AMRIT Pharmacies to 550 outlets by 2027

HLL Lifecare will significantly expand its AMRIT pharmacy network across India. The number of outlets will more than double to over 550 by December 2027. This initiative aims to make life-saving medicines and implants more affordable and accessible. Special focus will be on underserved and remote regions. The expansion involves an investment of Rs 100 crore.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5SmdnUW
via IFTTT

Read More

India set to lead global homoeopathy with certified quality frameworks: Experts

India is set to lead the global homoeopathy market. Strong clinical expertise and practitioner networks are driving this growth. Internationally recognised quality certifications like AYUSH Premium Mark and NABL accreditation are key. Indian brands are now well-positioned to challenge established European dominance. This marks a significant shift in the global homoeopathy landscape.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pObwAGH
via IFTTT

Read More

Middle East conflict hits medical tourism, Indian hospitals tap other markets

Indian hospitals are diversifying patient sources to Southeast Asia, Africa, and Central Asia as the Middle East conflict disrupts medical travel. This shift aims to mitigate revenue losses from the region, which contributes significantly to their medical value travel earnings. Hospitals are also enhancing teleconsultation services and seeking government support for direct flights to maintain patient inflows.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7cAkRfo
via IFTTT

Read More

Cipla recalls over 400 cartons of cancer drug in US: FDA

Cipla USA is recalling over 400 cartons of its anti-cancer drug Nilotinib Capsules. The recall is due to a manufacturing issue where the capsules failed to meet specifications. This is a voluntary Class III recall, meaning it is not expected to cause adverse health consequences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tdnVDy3
via IFTTT

Read More

FDA official overseeing vaccines resigns amidst controversy

A key US Food and Drug Administration official responsible for vaccines is departing at the end of April. Vinay Prasad faced criticism for health policy decisions, particularly concerning Covid-19 vaccine efficacy. His exit follows controversies, including refusing to review a flu vaccine application. Prasad had previously raised doubts about Covid-19 vaccine safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5WejPXN
via IFTTT

Read More

Key drug prices may surge on hoarding and higher demand

Escalating Middle East conflict is expected to increase demand for essential medicines. This surge could lead to higher drug prices, potentially benefiting Indian pharmaceutical manufacturers. Companies are monitoring the situation closely. Increased demand for chronic and acute therapy drugs is anticipated. Indian firms may see export disruptions but also higher overall demand if the conflict extends.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S615dwf
via IFTTT

Read More